Third Rock, GV back Broad spinout Celsius in bid to develop precision meds for autoimmune disease
Third Rock is teaming up with Google’s venture arm to back a gene therapy startup stepping out today with $65 million in new money. As you might expect with GV’s involvement, the new venture has a technology twist, and it might have its hands on something big for the autoimmune world.
Are you ready for a game of buzzword bingo? The startup, called Celsius Therapeutics, is using new tech in genetic sequencing (check) — and a proprietary machine learning (check) algorithm (check) — to tackle precision meds (check) for cancer (check) and autoimmune disease. I’ll break that down for you later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.